Economic impact of enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in patients with acute ischemic stroke: A hospital perspective of the PREVAIL trial-Reference-Cited by-同舟云学术

Economic impact of enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in patients with acute ischemic stroke: A hospital perspective of the PREVAIL trial

Published:2011-11-04 Issue:3 Volume:7 Page:176-182
ISSN:1553-5592
Container-title:Journal of Hospital Medicine
language:en
Short-container-title:J. Hosp. Med.

Author:

Pineo Graham,Lin Jay,Stern Lee,Subrahmanian Tarun,Annemans Lieven

Publisher

Wiley

Subject

Assessment and Diagnosis,Care Planning,Health Policy,Fundamentals and skills,General Medicine,Leadership and Management

Link

https://mdedge-files-live.s3.us-east-2.amazonaws.com/files/s3fs-public/pdfs/journals/968_ftp.pdf

Reference34 articles.

1. Venous thromboembolism: disease burden, outcomes and risk factors;Heit;J Thromb Haemost.,2005

2. The epidemiology of venous thromboembolism in the community: implications for prevention and management;Heit;J Thromb Thrombolysis.,2006

3. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study;Heit;Arch Intern Med.,2002

4. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study;Heit;Arch Intern Med.,2000

5. A safety analysis of thromboprophylaxis in acute medical illness;Alikhan;Thromb Haemost.,2003

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness, Safety, and Costs of Thromboprophylaxis with Enoxaparin or Unfractionated Heparin Among Medical Inpatients With Chronic Obstructive Pulmonary Disease or Heart Failure;Journal of Health Economics and Outcomes Research;2024-02-20

2. Effectiveness, Safety, and Costs of Thromboprophylaxis with Enoxaparin or Unfractionated Heparin Among Medical Inpatients With Chronic Obstructive Pulmonary Disease or Heart Failure;Journal of Health Economics and Outcomes Research;2024-02-20

3. Effectiveness, safety, and costs of thromboprophylaxis with enoxaparin or unfractionated heparin in inpatients with obesity;Frontiers in Cardiovascular Medicine;2023-06-16

4. Low-molecular-weight Heparin (enoxaparin) versus unfractionated heparin for venous thromboembolism prophylaxis in patients undergoing craniotomy;Clinical Neurology and Neurosurgery;2022-12

5. Pragmatic Recommendations for the Management of Anticoagulation and Venous Thrombotic Disease for Hospitalized Patients with COVID-19 in Low- and Middle-Income Countries;The American Journal of Tropical Medicine and Hygiene;2021-01-11